Journal
CELLULAR IMMUNOLOGY
Volume 212, Issue 2, Pages 118-125Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1006/cimm.2001.1852
Keywords
human; B cell; activation; IL6; vIL6; CD126 ' IL6R '; CD130 ' gpl30 '; IIHV-8; cytokine
Categories
Funding
- NCI NIH HHS [F32CA80610, CA73475, CA57152] Funding Source: Medline
- NIAID NIH HHS [T32AI07388] Funding Source: Medline
- NIAMS NIH HHS [CFAR AI28697] Funding Source: Medline
Ask authors/readers for more resources
Cellular responsiveness to human interleukin 6 (hIL6) requires the expression of two receptor molecules: IL6-specific receptor (CD126'IL6R') and a nonspecific signal-transducing molecule (CD130'gp130'). Regulation of responsiveness to hIL6 is generally controlled by CD126'IL6R' expression. A viral homologue of hIL6 (vIL6) is encoded by human herpesvirus-8 and has biologic activity similar to hIL6 on a number of cell lines. vIL6 differs from hIL6 in its receptor utilization, requiring only CD130'gp130'. Total human B cells isolated from peripheral blood, which are predominantly CD126'IL6R'-negative, as well as sorted CD126'IL6R'-negative B cells, could be stimulated by recombinant vIL6, but not by hIL6, as indicated by induction of IL6-like signaling (STAT3 phosphorylation). This suggests that the ability of vIL6 to stimulate B cells expressing little or no CD126'IL6R' allows it to act on a larger pool of target B cells, compared to human IL6. (C) 2001 Elsevier Science.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available